REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of Two Nitrogens And Four Carbon Atoms (e.g., Pyridazines, Etc.) > 1,4-diazine As One Of The Cyclos > Piperazines (i.e., Fully Hydrogenated 1,4-diazines) > Nitrogen Or -c(=x)-, Wherein X Is Chalcogen, Bonded Directly To The Piperazine Ring Nitrogen Or -c(=x)-, Wherein X Is Chalcogen, Bonded Directly To The Piperazine RingNitrogen Or -c(=x)-, Wherein X Is Chalcogen, Bonded Directly To The Piperazine Ring patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.12/21/06 - 20060287337 - Trans-golgi network-associated processes, methods and compositions related thereto The application discloses methods and compositions related to the modulation of trans-Golgi network-associated processes, including methods and compositions for the modulation of trans-Golgi network-associated proteins and methods for the treatment of disorders associated with trans-Golgi network processes. ... 11/02/06 - 20060247257 - Combination The invention provides a pharmaceutical composition, pharmaceutical product or kit comprising a first active ingredient which is a P2X7 receptor antagonist, and a second active ingredient which is an inhibitor of proTNFα; convertase enzyme (TACE), for use in the treatment of inflammatory disorders. ... 10/26/06 - 20060241124 - Combinations comprising paroxetine and 2- (s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-carboxylic acid [1- (r)- (3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide for treatment of depression and/or anxiety The present invention relates to therapeutic combinations comprising paroxetine or physiologically acceptable salts or solvates thereof and 2-(S)-(4-Fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or physiologically acceptable salts or solvates thereof, to pharmaceutical compositions containing said combinations and their use in the treatment of depression and/or anxiety. ... 10/19/06 - 20060235027 - Inhibitors of cdc25 phosphatases wherein the substituents are defined as in the specification. ... 10/12/06 - 20060229319 - Enantiomers of 1-[(4-chlorophenyl) phenylmethyl)-4-[(4-methylphenyl)sulfonyl] piperazine A method is disclosed for the treatment of an allergic condition associated with a cutaneous reaction induced by histamine. There is administered to a patient in need of such treatment the levorotatory dihydrochloride of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy] acetic acid. ... 09/28/06 - 20060217397 - Sustained release ranolazine formulations A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and ... 08/31/06 - 20060194817 - N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and ... 07/27/06 - 20060167011 - Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof and a process for making thereof. The compounds have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention also provides intermediate compounds useful in the process, as well as final products ... 06/29/06 - 20060142305 - Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates ... 06/22/06 - 20060135532 - Platelet adenosine diphosphate receptor antagonists where A, a, b, R1, R2, R3, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein. ... 06/08/06 - 20060122192 - Chemical compounds The invention relates to piperazine derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to their medical use. The novel compounds are antagonists of tachykinins, including substance P and other neurokinins. ... 04/20/06 - 20060084661 - Il-8 receptor antagonists This invention relates to the novel use of amide squaramides in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8). ... 04/20/06 - 20060084660 - Calcium channel blockers comprising two benzhydril moieties Certain piperazine compounds are described which are useful in altering calcium channel activity. ... 04/06/06 - 20060074091 - Nootropic effect enhancer (wherein R1 is a lower alkyl, etc.; R2 is hydrogen, etc.; R3 is an aryl, etc.; A is —CO—, etc.; X is N or CH; Y is —CO—, etc.), for attaining higher antidementic and/or antiamnesic potency. ... 03/30/06 - 20060069104 - Neurotrophic factor production accelerator wherein R1 is lower alkyl, aryl, ar(lower)alkoxy, or a heterocyclic group, and the above groups may be substituted with halogen, R2 is a hydrogen atom or lower alkyl, R3 is cyclo(lower)alkyl, aryl or ar(lower)alkyl, and the above groups may be substituted with halogen, A is —CO—, —SO2— or lower alkylene, ... 03/23/06 - 20060063778 - Hydroxamic acid derivatives Novel hydroxamic acid derivatives, e.g., of formula (I), wherein R1, R2, R3 and R4 are as defined, are found to be useful as pharmaceuticals, e.g., for the suppression of TNF release and the treatment of autoimmune and inflammatory diseases, e.g., multiple sclerosis and rheumatoid arthritis. Methods of making the compounds, ... 01/12/06 - 20060009470 - Method for specifically potentiating n-type ca2+ channel activity wherein R1 is lower alkyl, aryl, ar(lower)alkoxy or a heterocyclic group, the above groups being optionally substituted by halogen, R2 is hydrogen atom or lower alkyl, R3 is cyclo(lower)alkyl, aryl or ar(lower)alkyl, the above groups being optionally substituted by halogen, A is —CO—, —SO2— or lower alkylene, and Y shows ... 12/08/05 - 20050272744 - N-sulfonylcarboximidamide apoptosis promoters are apoptosis promoters. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds. ... 12/08/05 - 20050272743 - Prostaglandin derivatives Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension. ... 12/01/05 - 20050267127 - Guanidino phenylalanin compounds used as urokinase inhibitors The invention relates to the use of derivatives of 3-guanidinophenylalanine as urokinase inhibitors for treating malignant tumors and metastasis. ... 11/17/05 - 20050256133 - Thio-substituted arylmethanesulfinyl derivatives wherein Ar, X, Y, R1, R2, R3, and q are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity ... 10/13/05 - 20050227995 - Phenyl sulfoxides and phenyl sulfones The invention relates to phenyl sulfoxides and sulfones and processes for their preparation, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially Alzheimer's disease. ... 09/01/05 - 20050192289 - Novel cinnamic amides wherein X is chloro or fluoro and R1 is an aromatic or heteroaromatic group, their pharmaceutically acceptable salts or solvates. The invention also relates to pharmaceutical compositions containing a compound of formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of compounds of formula ... 08/11/05 - 20050176731 - Oxophenyl-cyclohexyl-propanolamine derivatives, production and use therof in therapeutics where n is equal to 0, 1 or 2, R4 and R5 represent H, a (C1-C4)alkyl, hydroxyl, cyano, phenyl, benzyl, piperidyl, —CONH2, —CO-phenyl, —COOR3, —CH(phenyl) (OH) and —C(phenyl)2(OH) group, or R4 and R5 form together an optionally substituted 6-membered aromatic ring, R6 represents H, a (C1-C4)alkyl, phenyl or benzyl group, ... 07/14/05 - 20050153982 - Sustained release ranolazine formulations A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and ... 07/14/05 - 20050153981 - Aralkyl formly-alkyl piperazine derivatives and their uses as a cerebral nerve protective agent Pharmaceutical compositions comprising the same, and methods of using them as a neuroprotective agent. Pharmaceutical results indicate that these compounds have excellent neuroprotective activities and fewer side effects. ... 06/30/05 - 20050143393 - Pleuromutilin derivatives with antimicrobial activity are of use in anti-bacterial therapy. ... 06/23/05 - 20050137210 - Substituted n-aryl amidines as selective d1 dopamine receptor antagonists for the treatment of obesity and cns disorders The present invention provides compounds, which, are novel antagonists for D1 receptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprising such D1 receptor antagonists as well as methods of using them to treat CNS disorders, obesity, metabolic disorders, eating disorders such ... 06/02/05 - 20050119276 - Methods of treating inflammatory bowel disease using nf-kb inhibitors The present invention concerns a method of treating inflammatory bowel disease by diagnosing that a person is in need of treatment for inflammatory bowel disease and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-α, estrogen receptor ER-β, or both ... 06/02/05 - 20050119275 - Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2r,5s)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid This invention relates to salt and crystal forms of (5-chloro-2-{2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid, useful in treating or preventing a disorder or condition by antagonizing the CCR1 receptor, and to their methods of preparation and use. ... ### FreshPatents.com Support |